Skip to Content

Vaxart Inc VXRT

Morningstar Rating
$0.70 +0.03 (4.32%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

VXRT is trading at a 766% premium.
Price
$0.68
Fair Value
$9.88
Uncertainty
Extreme
1-Star Price
$98.43
5-Star Price
$8.67
Economic Moat
Mcnc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VXRT is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.67
Day Range
$0.660.70
52-Week Range
$0.521.54
Bid/Ask
$0.69 / $0.70
Market Cap
$124.38 Mil
Volume/Avg
625,724 / 4.1 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
9.75
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
109

Comparables

Valuation

Metric
VXRT
ENTA
AVIR
Price/Earnings (Normalized)
Price/Book Value
2.141.830.60
Price/Sales
9.754.14
Price/Cash Flow
Price/Earnings
VXRT
ENTA
AVIR

Financial Strength

Metric
VXRT
ENTA
AVIR
Quick Ratio
2.766.2313.11
Current Ratio
3.146.4313.28
Interest Coverage
−39.51−12.14
Quick Ratio
VXRT
ENTA
AVIR

Profitability

Metric
VXRT
ENTA
AVIR
Return on Assets (Normalized)
−64.44%−25.87%−20.62%
Return on Equity (Normalized)
−96.46%−50.83%−21.76%
Return on Invested Capital (Normalized)
−75.44%−46.23%−25.76%
Return on Assets
VXRT
ENTA
AVIR
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
KgrqfhyqqJvnp$589.6 Bil
Vertex Pharmaceuticals Inc
VRTX
YpsvtlzMjmfzj$126.9 Bil
Regeneron Pharmaceuticals Inc
REGN
LktlsgnBccszz$117.2 Bil
Moderna Inc
MRNA
FcrlsfmhCcy$46.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
XspygqpDqbpktg$30.1 Bil
argenx SE ADR
ARGX
HxdnrvbzcGmmg$28.0 Bil
BioNTech SE ADR
BNTX
ZtqztjywyJhpts$20.6 Bil
Biomarin Pharmaceutical Inc
BMRN
FbmqbqntpWzflwy$16.0 Bil
United Therapeutics Corp
UTHR
WdsxqlnkqCgg$14.6 Bil
Incyte Corp
INCY
JgmhhfqzTwdgzks$13.0 Bil

Sponsor Center